The city of Tallahassee, Florida, currently has 3 active clinical trials seeking participants for Multiple Sclerosis research studies.
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Recruiting
To evaluate the safety and efficacy of fingolimod vs. interferon beta-1a i.m. in pediatric patients with multiple sclerosis (MS)
Gender:
All
Ages:
Between 10 years and 17 years
Trial Updated:
04/22/2024
Locations: Novartis Investigative Site, Tallahassee, Florida
Conditions: Multiple Sclerosis
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Recruiting
The purpose of this study is to collect long-term safety, tolerability, effectiveness and health outcomes data in eligible subjects who have participated in a Novartis ofatumumab clinical MS study. Vaccination sub-study The purpose of this research sub-study is to find out the effects of ofatumumab on the development of antibody responses to selected vaccines and keyhole limpet hemocyanin (KLH) neo-antigen in subjects with relapsing multiple sclerosis (RMS).
Gender:
All
Ages:
Between 18 years and 100 years
Trial Updated:
04/17/2024
Locations: AMO Corporation, Tallahassee, Florida
Conditions: Relapsing Multiple Sclerosis
Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.
Recruiting
This study will evaluate the impact of ofatumumab in Relapsing Remitting Multiple Sclerosis (RRMS) participants that are very early in the course of their disease using clinical and magnetic resonance imaging (MRI) outcomes. The study will also assess changes in disease using monitoring techniques including digital biometric device use, biomarker analysis and non-conventional MRI. Select outcomes in the ofatumumab treated group will be compared to a group of Healthy participants to determine if... Read More
Gender:
All
Ages:
Between 18 years and 35 years
Trial Updated:
02/01/2024
Locations: Novartis Investigative Site, Tallahassee, Florida
Conditions: Relapse Remitting Multiple Sclerosis